Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
Date:6/28/2010

RARITAN, N.J., June 28 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the signing of a five-year collaboration agreement with the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.  Called TRANSCEND, the collaboration agreement will foster oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, and profiles of the tumor microenvironment.

"The TRANSCEND program embodies our external innovation approach to research," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Oncology, for Johnson & Johnson Pharmaceutical Research & Development, L.L.C., an affiliate of Ortho-McNeil Janssen.  "By collaborating with leading academic institutions and colleagues at the interface of engineering and biology, we're able to bring together the best scientific minds in industry and academia to meet unmet medical needs in patients with cancer."

A Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees will jointly review and select proposals from MIT researchers for funding.  Projects will involve interdisciplinary faculty, students and staff to address oncology solutions.  In addition, there is the potential for visiting scientists from Ortho-McNeil Janssen to participate in projects within the investigators' laboratories at the Koch Institute.

"The visiting scientist aspect of the program is designed to promote interactive exchange between our organizations
'/>"/>

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
5. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... -- Women everywhere know how frustrating a vaginal infection ... often also embarrassing and have a way of derailing ... http://ph-defense.com ) is a new, over-the-counter product designed to ... Odor, discharge, and discomfort or itch ... many cases, the cause of such problems can be ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... of its public offering of 4,500,000 shares of its common ... $9.25 per share. Aratana has granted the underwriters ... additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today ... midazolam injection, USP, a general anesthetic.  Sagent expects ... latex-free vials, in 2011.  According to 2010 IMS ... approximated $52 million.   "Approval of ...
... Genous Stent shows favorable outcomes compared to bare metal stents ... to data published online in the journal Atherosclerosis ... primary endpoint, the composite of cardiac death, myocardial infarction (MI) ... 12.4% in patients treated with a Genous Stent, a 30% ...
Cached Medicine Technology:Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP 2OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents 2
(Date:9/17/2014)... University] As Congress adjourns this month for the ... step over on their way out the chamber door ... Medicare Provider Payment Modernization Act of 2014. In a ... Dr. Eli Adashi recounts what he and other advocates ... The perennial trouble with how Medicare pays doctors will ...
(Date:9/17/2014)... 17, 2014 Wright hip lawsuit ... of metal-on-metal hip replacements continue to grow in ... Court, Northern District of Georgia, Bernstein Liebhard LLP ... by the U.S. Judicial Panel on Multidistrict Litigation ... liability claims have been filed in the proceeding ...
(Date:9/17/2014)... 2014 Boston Children’s Museum and ... monthly concert series, introducing young Museum visitors to ... America’s premier national platform celebrating the stories, talents, ... the young musicians featured will also be showcased ... Museum is fortunate to partner with the wonderful ...
(Date:9/17/2014)... Austin, TX (PRWEB) September 17, 2014 ... the Editor’s Picks by Progressive Grocer, a leading trade ... Pizza was awarded for originality and flavor, among other ... featured as an Editor’s Pick in the September print ... Progressive Grocer website. , The pizza won based on ...
(Date:9/17/2014)... 17, 2014 StartX , a ... companies raising rounds of funding at its Summer Demo ... investors and media, was the first such gathering held ... to the university. The presentations were delivered on an ... StartX-QB3 Labs, a 2,000 square foot life science facility ...
Breaking Medicine News(10 mins):Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... for the purpose of drug testing which is currently ... at the University of Manchester, well supported with a ... carcinogenic effects of new drugs are often fruitless using ... animals to establish their safety. ,Gentronix , a ...
... are the latest to join the fight against HIV with ... clients.// They have been recruited as part of an innovative ... the British government. This donation is expected to aid in ... by increasing testing and encouraging safer sex. ...
... gain at bay, says a Rhode Island researcher. Much like ... dismissed// as the fertile imagination of a maverick researcher, which ... control programmes. And while you weigh the pros and cons ... story of why the most famous ‘don’t’ of almost all ...
... Fresh statistics show a phenomenal rise in sexually transmitted ... of the most common treatable sexually transmitted diseases affecting ... in its incidence rates across the Australian subcontinent. with ... younger age groups with no gender distinction among the ...
... Haryana: This one's a very different kind of war for ... some. You bomb bacteria, not civilian populations//. And the retired ... the past 13 years. ,What began in 1993 ... and Leprosy Eradication (ABLE). Made possible through generous NRI funding ...
... Diligent study has helped telemedicine researchers at University of Queensland ... virtually shrinking ominous distances between cities and remote settlements in ... Eliza was created by the Centre for Online Health one ... Which is affiliated to the University of Queensland, Eliza ...
Cached Medicine News:Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Tilt the Scales in Your Favor by Simply Weighing Yourself Everyday! 2Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2Health News:Robots Help Bring Specialist Doctors To You In A Trice 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: